{"analyses":[{"ciLowerLimit":"6.87","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.97","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","pValueComment":"The Hochberg procedure was used to control for multiplicity.","paramType":"Difference from Placebo","paramValue":"7.92","statisticalComment":"Model includes treatment group as the independent variable and adjusted for baseline value and the randomization stratification factors.","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.06","upperLimit":"-2.58","value":"-3.32"},{"groupId":"OG001","lowerLimit":"3.85","upperLimit":"5.35","value":"4.60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"237"},{"groupId":"OG001","value":"231"}],"units":"Participants"}],"description":"Bone mineral density was assessed by dual x-ray absorptiometry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to receive the matching placebo subcutaneously (SC) once every 6 months (Q6M) in the double-blind phase. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.","id":"OG000","title":"Placebo"},{"description":"Participants randomized to receive 60 mg denosumab SC once Q6M in the double-blind phase. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.","id":"OG001","title":"Denosumab"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"BMD Analysis Set: all participants with total hip BMD evaluable values at Baseline and Month 36","reportingStatus":"POSTED","timeFrame":"Baseline and Month 36","title":"Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites","type":"SECONDARY","unitOfMeasure":"Percent Change in BMD"}